The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) decreased by $0.0 on Wednesday to $0.23, down -2.98 percent. The last five days have seen an average of 958,788 shares of common stock traded. 12 times new highs were reached in the current year, with a gain of $0.1090. The average number of shares traded over the last 20 days was 1,041,462, while the average volume over the last 50 days totaled 1,534,143.
VBLT stock dropped -17.99% since last month. On 08/14/23, the company’s shares reached a one-month low of $0.2099. The stock touched a high of $0.32 on 07/13/23, after rallying from a low of $0.10 in 52 weeks. The price of VBLT stock has risen by 90.00% or $0.1090 this year, reaching a new high 12 times. Still, the stock price is down -28.75% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Beta for the stock is 0.82. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 34.89, the price-to-book (PB) ratio of 0.88.
Financial Health
For the three months ended September 29, Vascular Biogenics Ltd.’s quick ratio was 3.50, while its current ratio was 3.50, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 90.60% percent. Based on annual data, it had gross profit of $0.55 million and revenue of $0.66 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. VBLT’s return on assets (ROA) during the last 12 months has been -70.70%. There was a -146.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -96.10%.
Earnings Surprise
According to Vascular Biogenics Ltd.’s quarterly financial report for the quarter that ended September 29. It was predicted that Vascular Biogenics Ltd.’s quarterly earnings would be -$0.12, but it ended up being -$0.11, beating the consensus by -9.10%. EBITDA was -$0.51 million for the quarter.
Technical Picture
Here’s a quick look at Vascular Biogenics Ltd.’s (VBLT) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 32.75%, suggesting the stock is Neutral, with a 69.73% historical volatility rate.
The stochastic %K and %D were 24.57% and 22.93% respectively, while the average true range (ATR) was 0.0252. Based on the 14-day stochastic reading of 19.47%, the RSI (14) reading is 38.39%. On the 9-day MACD Oscillator, the stock is at -0.0088, and the 14-day reading is at -0.0256.
Analyst Ratings
Vascular Biogenics Ltd. (NASDAQ: VBLT) was downgraded by Oppenheimer to a a Perform rating in its latest research report. The stock was previously rated as a an Outperform. Analysts have assigned Vascular Biogenics Ltd. (VBLT) an Hold rating. VBLT is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is VBLT’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $5.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for Vascular Biogenics Ltd. (VBLT) is $5.00.
